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Abstract
Background: Monoclonal antibodies (mAbs), as an emerging technology, have become increasingly important in
the development of human therapeutic agents. How developing countries such as China could seize this emerging
technological opportunity remains a poorly studied issue in prior literature. Thus, this paper aims to investigate the
research and development of mAbs in China based on an innovation system functions approach and probes into
the question of how China has been taking advantage of emerging technologies to overcome its challenges of
building up a complete innovation system in developing mAbs.
Methods: Mixed research methods were applied by combining archival data and field interviews. Archival data
from the China Food and Drug Administration, Web of Science, the United States Patent and Trademark Office, the
Chinese Clinical Trial Registry, and the National Science and Technology Report Service were used to examine the
status quo of the technology and research and development (R&D) activities in China, while the opinions of
researchers and managers in this field were synthesized from the interviews.
Results: From the perspective of innovation system functions, technological development of mAb in China is being
driven by incentives such as the subsidies from the State and corporate R&D funding. Knowledge diffusion has
been well served over the last 10 years through exchanging information on networks and technology transfer with
developed countries. The State has provided clear guidance on search of emerging mAb technologies. Legitimacy
of mAb in China has gained momentum owing to the implementation of government policies stipulated in the
“The Eleventh Five-year Plan” in 2007, as well as national projects such as the “973 Program” and “863 Program”,
among others. The potential of market formation stays high because of the rising local demand and government
support. Entrepreneurial activities for mAb continue to prosper. In addition, the situation of resource supply has
been improved with the support of the State.
Conclusions: This study finds that a complete innovation system for mAb has begun to take shape in China. MAb
innovators in China are capitalizing on this emerging technological opportunity to participate in the global drive of
developing the value chain for the innovative drug. In the long run, the build-up of the research system for mAb in
China could bring about more driving forces to the mAb innovation system.
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Background
Over the past three decades, monoclonal antibodies
(mAbs) have made a dramatic transformation from sci-
entific tools to powerful human therapeutic agents [1].
Sales of mAb therapies exceeded 40 billion US dollars in
2010 and are expected to reach 70 billion US dollars by
2015 [2]. In 1975, Koehler and Milstein first described
the in vitro production of murine mAbs from hybrid-
omas [3]. In the late 1980s, clinical development of mur-
ine mAbs was initiated but then inhibited by numerous
significant drawbacks [4]. Later, in an attempt to over-
come the inherent immunogenicity concerns and the re-
duced effect or function of murine mAbs in human [5],
chimeric mouse-human antibodies were developed [6].
Nowadays, humanized mAbs are the fastest growing cat-
egory of mAb therapeutics entering clinical study [7].
Development of this class of therapeutic agents started
as early as 1980s but achieved no clinical or commercial
success until 2002, when adalimumab became the first
humanized mAb approved by the United States Food
and Drug Administration [8]. Thus far, a total of seven
humanized mAbs have been approved for marketing in
the United States.
While mAbs, as an emerging technology, have become
increasingly important in the development of human
therapeutic agents, how developing countries such as
China could seize this emerging technological opportun-
ity remains a scantly studied topic in prior literature.
Aiming at investigating mAb development in China by
drawing on an innovation systems approach, this paper
probes into the question of how China has been taking
advantage of emerging technologies to overcome chal-
lenges through building up an innovation system in de-
veloping mAbs. In so doing, it attempts to contribute to
(1) an understanding of the establishment and structure
of the mAb innovation system in China; (2) an evalu-
ation of the performance of the mAb innovation system
by analysing the functions of the innovation system; and
(3) providing policy suggestions for improving the mAb
innovation system.
Further, this paper offers an overview of the functions
of innovation system approach, which provided the the-
oretical framework for examining the mAb innovation
system, and analyses the innovation system of mAbs and
the function fulfilment. To deepen the theoretical under-
standing, we discuss the research findings by comparing
the Chinese mAb innovation system with that of the
United States and India, as well as with innovation sys-
tems of Chinese pharmaceuticals, concluding with les-
sons from the managerial and policymaking perspective.
Theoretical framework
Emerging technologies, such as mAbs, are expected to
contribute to technology advances, economic development,
and environmental and health improvements [9–14]. How-
ever, compared with traditional technologies, emerging
technologies are newly introduced, fast changing and de-
veloping, and have relatively limited applications in the
market, which is characterized by greater measures of un-
certainty [15–18]. Therefore, the development and
commercialization of emerging technologies are heavily
dependent on the establishment and operation of an
innovation system [19].
For an emerging technology, the idea of a technological
innovation system was considered as a new method to
understand the dynamic changes of technological progress
[20]. The technological innovation system is regarded as
(1) “a heuristic attempt, developed to analyse all societal
subsystems, actors, and institutions contributing in one
way or the other, directly or indirectly, intentionally or
not, to the emergence or production of innovation” [21,
22]; and (2) a systematic combination of actors, networks,
and institutions [23, 24]. Therefore, the framework of
technological innovation systems provides an effective
means to study emerging technologies such as mAb.
Traditional innovation systems studies mainly con-
centrate on the system structure, which has been
proven to be insufficient to identify policymaking rec-
ommendations [25]. Thus, an in-depth analysis of
innovation systems is warranted to understand the in-
fluence of a series of processes called “functions” [25].
Once known what innovation systems functions pro-
mote or hinder the innovation, policies and manage-
ment activities that are necessary for improving the
innovation system can be easily identified [26].
Innovation systems functions are interpreted in seven
dimensions, as indicated below [27–29]:
 Function 1: Entrepreneurial activities
Entrepreneurs are of prime importance; without
entrepreneurs, no innovation system would take
place. What the entrepreneurs do is turn the potential
of a new technology into concrete action and take full
advantage of business opportunities [30].
 Function 2: Knowledge development (learning)
If solutions to identified problems are to be
provided, new technologies must be developed.
Research and development (R&D), search and
experimentation, learning-by-doing/using and
imitation are regarded as possible sources of new
technologies. They may combine old and new
technologies in innovative ways and reuse old
knowledge by imitation [31].
 Function 3: Knowledge diffusion through networks
Exchanging information is the essential
characteristic of networks, such as changing norms
and values. The diffusion may lead to a change in
R&D agendas [32].
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 Function 4: Guidance of the search
Activities can positively affect the visibility and
clarity of specific needs [30]. Expectations are also
included.
 Function 5: Market formation
It is difficult for emerging technologies to compete
with embedded ones. Therefore, it is important to
create protected markets for new technologies by
formation of temporary niche markets and tax
regimes of minimal consumption quotas [33].
 Function 6: Resource mobilization
Both finance and human capital are necessary for all
the activities within innovation systems [21]. They
may determine the success or failure of a project.
 Function 7: Advocacy coalition (creation of
legitimacy/counteract resistance to change)
In order to become a well-developed technology,
emerging technologies must be part of an incumbent
regime. Parties with vested interests will often oppose
the force of ‘creative destruction’. Thus, advocacy
coalitions can function as a catalyst to place a new
technology on the agenda. If successful, advocacy
coalitions grow in terms of size and influence and can
become powerful enough to brisk up the spirit of
creative destruction [22].
Methods
In an attempt to provide a comprehensive research of
mAbs development in China, this study employed a
multi-dimensional design to enhance the rigor and rele-
vance of the study [34–36]. Thus, multiple data sources
are used to serve the purpose. Basically, our approach
consists of retrieving a wide range of activities using a
variety of sources related to the development and diffu-
sion of the technology under study.
Firstly, archival data were collected from multiple
sources, as listed below.
 Product registry
Database in China Food and Drug Administration
was searched to confirm the exact number of
domestic mAb products approved in China.
“Biopharmaceutical drugs” as a category was
selected in “domestic products”, and “monoclonal
antibody” was used as a keyword; diagnostic
antibodies and diagnostic agents were excluded.
 Patent
The search strategy was defined as the mAb patents
applied by Chinese Applicants in recent decades in the
United States Patent and Trademark Office. Patent
information with satisfactory purposes was searched
using the following strategies: Topic = (monoclonal
antibod*) AND Title = (monoclonal antibod*) AND
Assignee = (CHINA). There was no limit to the year.
 Publication
Academic publications related to mAbs in China
were extracted from the Thomson Reuters’ Web of
Science database. Studies and research about mAbs
in China began in the 21st century [37]. Publications
related to mAbs between 2000 and 2013 were
searched using the following strategies: Topic
= (monoclonal antibod*) AND Title = (monoclonal
antibod*) AND Address = (China not Hong Kong
not Taiwan not Macau). “mAbs” was used as the
keyword in the same way. In the query above, the
asterisk (*) represents any group of characters or no
character and the literature type was limited in
“Article”. Given a better understanding about the
position of China’s mAbs in the world, publication
status of anti-tumour mAbs in China was chosen as
an example and compared with “Top 5” countries
with respect to mAbs. While keeping the database
updated, all the data used were as recent as until
March 21, 2014. Selected documents included
“monoclonal antibod* or mab*” in the title or
“monoclonal antibod* or mAb*” in the topic, and
“cancer or tumor or anti-cancer or anti-tumor” in
the topic. “Address” searched for the selected countries
and regions, including China (excluding Hong Kong,
Taiwan and Macau), United States, Japan, Germany,
United Kingdom, Italy, France, the Netherlands, and
Canada. The document type was limited in “Article” as
well. The publication years covered were from 1980 to
2013, since commercially sponsored mAbs began
entering clinical study in 1980 [38].
 Clinical trials registry
The Chinese Clinical Trial Registry database was the
source used to present situations about assignees
and funding of clinical trials applied in China on
mAbs. Both Chinese and English databases were
used to search and sort records. “mAb” and
“monoclonal antibody*” were used as keywords; the
year was not limited.
 Research projects
The National Science and Technology Report
Service database, which offers open access, was
searched to ascertain and narrow down the list of
targeted key mAb institutions.
In addition, field interviews were conducted to collect
the relevant information. Expert, rather than general or
informal, opinions play a crucial role and are often
sought for professional advice in the development of
technology and policy change to enhance knowledge of
emerging technologies such as the mAb industry, even
though the information may reveal the risks, benefits
and regulations involved [39, 40]. For the purpose of
this study, a series of interviews were conducted with
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six Chinese researchers specialized in mAbs and man-
agers from three leading Chinese mAb firms. The in-
terviewees were identified through the National
Science and Technology Report Service database. The
interview design was reviewed and approved by the
Ethics Committee of the University of Macau. The
chosen interviewees were contacted through email
first to obtain their consent. The interview questions
did not involve confidential information but were just
designed from the perspectives of technology, the
characteristics and strategies of R&D, and the chal-
lenges and technical obstacles, among others. In
addition, some documentary materials were also re-
ferred to [41–43].
With all the material collected from the multiple
sources described above, we conducted the data analysis
in two stages. First, following the components of techno-
logical innovation system, we categorized the materials
into four aspects: mAb technology development, mAb
firms, research institutes and their networking with
firms, and institutions. All the quantitative and qualita-
tive materials were used as complementary and used to
cross-check our findings. Second, based on the results of
the first stage, we analyzed the functions of mAb
innovation systems in terms of the seven dimensions as
defined above. Such an analysis framework for techno-
logical innovation system has been widely validated in
the study of emerging technologies, and it is therefore
appropriate to apply this kind of analysis framework to
analyse mAb innovation systems. The final results of
analysis are reported in the next two sections.
mAb innovation systems in China
Stages of mAb technology development in China
mAbs in China were originally developed from the
tracking of existing technologies. Having prepared itself
for the new opportunity on a theoretical basis, China
commenced engagement with researchers and devel-
opers of other countries in order to allow the cutting-
edge technology to flow in directly. Into the 21st cen-
tury, Chinese mAb R&D finds itself at a more mature
stage with an established production platform and pat-
ented innovative drug activities impending. The develop-
ment of mAbs in China could be summarized as
consisting of the following stages:
 Absorbing stage
Tracking the cutting-edge technology from foreign
countries was the objective at this stage, with the
advent of its own publications on the existing
foreign mAb agents as well as the local R&D pro-
cesses. China was preparing the first domestic mAb
products for introduction into the market.
 Exploratory stage
By buying and the introducing the technology,
domestic products were listed on the market. By the
year 2006, four local agents had been developed,
including “me-too” and “me-better”. The number of
publications concerned was accumulating. Literature
types not only included reviews but also new-phased
research results. At this stage, China started
performing joint research with developed countries
such as the United States to explore the path to
independent studies.
 Innovation stage
At this stage of China’s mAb evolution, a total of
eight domestic products were available, some of
which had reached the stages of humanized
technology. The mAb agents were gradually
expanding with abundant indications in the process.
The R&D institutes attempted to push for United
States Patent and Trademark Office approval of
their domestic products and succeeded in 2006. The
content of the patents in general was concentrated
on the diagnosis of major diseases such as cancer
and also on mAb preparation and production
methods. The number of clinical trials for second
and third generation anti-cancer products increased
rapidly. Moreover, it was found that enterprises
whose products had been put into the market had
invested more effort and funding in clinical trials,
hence becoming the main sponsors in China.
mAb firms in China
While there are still few original innovation drugs devel-
oped in China, the status quo of foreign players dominat-
ing the Chinese mAb market has now changed. R&D of
mAbs in China began in the 1980s, but it was not until
1999 that the first mAb therapeutic agent was introduced.
To date, there are seven domestic companies with eight
products launched. Of the seven, four are producing “me-
too” or “me-better” drugs (Table 1). However, the prod-
ucts have no property rights of their own. These small and
medium-sized enterprises are typically with of a fragile
foundation and early-stage high R&D costs, as a result of
which they cannot afford the cost of long-term clinical tri-
als, but rely heavily on imported technology. Thus, most
focus on manufacturing instead of technology develop-
ment aiming at the domestic market only.
The rest, led by Shanghai CP Guojian pharmaceuticals
(CPGJ), have been growing steadily and trying to transform
“following” into “innovation”. Therefore, they take full ad-
vantage of pertinent policies and national research projects
to organize future-proof R&D activities. Their development
path represents the future direction of Chinese mAbs.
 Taixinsheng, produced by Bio-tech pharmaceuticals
and approved in 2008 had been the first outcome of
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national-level projects among developing countries.
Substantial support was provided by the government
program between China and Cuba, thus Bio-tech
performed as an important cooperative carrier of
R&D technology on nasopharyngeal cancer.
 Based in east Shanghai, Shanghai CPGJ, was
founded in 2002 and was jointly invested by China
International Trust and Investment Corporation and
Shanghai Lansheng Guojian pharmaceutical
company limited. CPGJ made a joint R&D effort
with the Second Military Medical University, one of
earliest Chinese military universities. CPGJ’s
products include mAb (Jiannipai, developed for
kidney transplantation) and fusion protein (Yisaipu,
developed for rheumatoid arthritis, etc.). Yisaipu has
been successfully listed in the National Medical
Insurance of numerous provinces and has
consequently earned large-scale government orders.
Further, CPGJ owns the intellectual property rights
solely.
 Huasun Biotech, established in 2005, is a subsidiary
of the Chengdu Huasun Biological Technology
Company Limited with listing in Shenzhen since
1998. Huasun Steel Structure, another Huasun
subsidiary, provided a steady and stable inflow of
cash. Moreover, Huasun Biotech seized the chance
to enter the biopharmaceutical market by
technology transfer from the Fourth Military
Medical University. The product, Licartin, is the first
domestic mAb for hepatocellular carcinoma.
While the domestic actors imported and absorbed a
mature technology, the price of domestic mAb products
still remains high, which suggests enormous mass pro-
duction costs for the local manufacturer. Therefore, im-
proving the capacity for efficient and advanced antibody
expression is conducive to cutting the costs.
Apart from CPGJ and Bio-tech, the remaining com-
panies mainly concentrate on the domestic market at
present. On the one hand, the demand of antibody-
based drugs is rather high, whereas producers of this
kind of therapy agents are far from being adequate. On
the other hand, their overall performance and competi-
tiveness are just as inadequate for exportation of their
products. To change this and open up international mar-
kets in the future, it is imperative for both policymakers
and corporations that actions should be taken at this
juncture.
Research institutes and their networking with firms
In 1980s, China began implementing mAb research ac-
tivities between the leading academic institutions at the
national level. Led by the Chinese Academy of Sciences,
the R&D institutions that were first established in 1949
when the Republic was founded, mostly with a military
background, are centred on the upstream and middle
reaches of leading antibody technologies. Their research
areas are gene cloning, cell engineering and platform es-
tablishment, etc. For instance, CPGJ has ongoing part-
nerships in key technologies with the Second Military
Medical University for mAb joint development. Suc-
cesses in marketing Licartin are owed to the founda-
tional technology transfer from the Fourth Military
Medical University to Huasun in 2000.
The establishment of the institutions dates back to the
last century. There has been great progress made in re-
cent years, with bountiful results achieved by the institu-
tions. They focus on R&D of upstream technology and
transfer the basic technology to enterprises for produc-
tion (Table 2), thus achievements from academic institu-
tions make up the majority of the new drugs (Licartin
and Yisaipu are a case in point). Meanwhile, academies
are facing difficulties such as those associated with hu-
manized antibodies and purification in the development
of mAbs. To overcome the obstacles and lead to a
brighter future, support from the government is deemed
essential.
On the one hand, the government encourages domes-
tic academies to take full advantage of national research
projects and to cooperate with domestic enterprises. On
the other, it explores new opportunities to connect with
the leading foreign players for resource sharing. For
Table 1 Leading actors (industry) of mAbs in China
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instance, Institute Pasteur of the Shanghai Chinese Acad-
emy of Science was co-built for the purpose of biothera-
peutics by the Chinese Academy of Sciences, Shanghai
Municipality, and Institute Pasteur (France) in 2004.
The research-oriented institutions are making efforts
to catch up with the advanced technology and work with
businesses for industrialization. However, at present, few
domestic products have had successful sales in China.
The interaction between academies and enterprises is a
rarity; as a result, most scientific research findings could
not be translated into productivity. Although the organic
integration of enterprises, universities and research insti-
tutes is recognized as a suitable mechanism and an eco-
nomic developing mode for the biopharmaceutical
industry in China, it is contingent on the support by the
policy for the mAbs industry to open up its avenue for
rapid development.
Institutions
Policies concerning mAbs are always under the guidance
of the government with respect to R&D in biotechnology.
Since 1987, Chinese authorities in the field of biotechnol-
ogy have issued a series of policies to promote and
standardize the development of the whole industry. The
main government agency in charge of policymaking is the
State Council and its subsidiary National Development
and Reform Commission, along with the Ministry of Sci-
ence and Technology. Early key drivers, such as The Sev-
enth Five-Year Plan, aimed at laying a foundation for
further technology development; whereas the “863” Pro-
gram (in 1986) and the “973” Program (in 1997) aimed at
tracking industry development trends of developed coun-
tries at the strategic level. During the past 20 years, China
has set clear targets for and a political commitment to the
biopharmaceutical industry with major progress made in
the current century.
Over nearly two decades, several state policies have
been issued to support business finance, drug approval,
marketing, and R&D in the biopharmaceutical industry.
The policy direction of basic subjects like genome engin-
eering and proteomics paved the way for mAbs develop-
ment. Under the guidance of the “863” (in 1986) and the
Table 2 Latest projects report related mAbs in 2013
Project Institution of first author Keywords
Humanized and human mAbs structure
and antibody optimization techniques
Academy of Military
Medical Science
Antibody humanized, human antibody,
expression system, analysis system
Final report of tumour and autoimmune
disease of certain target antibody drug design
Academy of Military
Medical Science
Molecular simulation, molecular docking,
target, BLyS, DR5, TNF




Antibody engineering drugs, immune coupling
objects, antibody fusion protein, synergistic
technology
Tumour marker optimization and clinical
research and protein chip development
Second Military Medical
University
Tumour marker, detection, protein chip,
breast cancer, pancreatic cancer, primary
liver cancer, colorectal cancer
Targeted complement inhibitor for systemic
lupus erythematosus (SLE)
The People’s Liberation
Army Institute for Disease
Control and Prevention
SLE, alexin, CR2, targeted inhibition,
physiology of immune defence
Studies on the novel technologies and
approaches for tumour immunotherapy
Fourth Military Medical
University
Tumour, immunotherapy, tumour vaccine,
erbB2/HER2, apoptosis, exosome




Auto-immune disease, antibody drug,
clinical therapy, mechanism investigation
Study on the new methods for diagnosing
nasopharyngeal carcinoma in early stage
Sun Yat-Sen University Nasopharyngeal carcinoma, Epstein-Barr virus,
tumour biomarker, Bmi-1, CNEPF, LMP2A, IFI27
Immunological recognition, immune regulation
and basic research of related immune diseases
Second Military Medical
University
Immunological recognition, immune tolerance,
related immune diseases
Common malignant tumour prevention, early
detection and comprehensive treatment research
Sun Yat-Sen University nasopharynx cancer, screening, early detection,
Epstein-Barr virus, pathogenesis
Research and development of novel tri-specific





Ovarian, tumour, antibody drug, specific
Passing report of 973 project “personalized immunosuppression
plan of transplant patients”
Huazhong University of
Science and Technology
Galectin-7, galectin-9, SNP, MDR1, IL-6, rejection,
immune tolerance, proteomics
Acceptance report of basic research on organ
transplantation immunology & application
Zhejiang University Organ transplantation, transplantation immunology,
chronic dysfunction, transplant infections,
immunosuppression
Information retrieved from the National Science and Technology Report Service (www.nstrs.cn) database (until December 2013).
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“973” (in 1997), and since the beginning of The Eleventh
Five-year Plan, the antibody industry has been regarded
as a major national innovative project, with its strategic
position being thus formally established. It was the same
with the developing path of the biological industry in
that mAb development was spearheaded by academic in-
stitutions to be gradually transformed into enterprises in
the ensuing years.
In 2006, the State called upon enterprises to take part
in the development of the technology by putting forward
a series of ordinances, programmes and policy changes,
including the “National Program for Long- and
Medium-term Scientific and Technological Development
(2006–2020)”, “Biological Industry Development of The
Eleventh Five-Year Plan”, “Policies to Speed up the De-
velopment of Biological Industry” and “The Twelfth
Five-Year Plan”, which accelerated high-tech enterprises’
endeavours to become the mainstay in independent
innovation. The policies thus initiated a focus on gene
drugs and antibody R&D in 2006, while it was also the
first time to affirm the long-term development of mAbs.
Up until 2009, four out of nine major projects had an
involvement in the biological pharmaceutical field; at
same time, the China Food and Drug Administration ex-
tended the duration of the state first-class new medicine
to 12 years through the revision of two main regulations
on new drug approval and technology transfer to en-
courage the development of innovative drugs, conse-
quently streamlining R&D and manufacturing. The
“Several Policies to Speed up the Development of the
Biological Industry” program in 2009 expanded the fi-
nancing channels and introduced risk investment to the
fast-increasing investment of private industries. Details
are shown in Table 3.
In summary, China implemented policies from three
main perspectives: market, enterprises, and academies.
Further, it made efforts to maintain a stable market en-
vironment and to establish a competitive system for
mAbs. Additionally, the government provided aid to
main business actors to encourage cooperation among
themselves and networking with academies, which led to
the beneficiaries eventually achieving positive results in
a phase by phase basis. Being closely connected with the
foundation of the mAb industry, policies also played an
important role in pushing mAb development forward
considerably. In the process of industrialization, R&D in
mAbs had changed from the state of “following suit” to
innovating and keeping updated not only in laboratory
studies but also in manufacturing. Finally, in order to
ensure that enterprises are the main body of innovation
and that small- and medium-sized enterprises were in-
volved in the development, effective long-term programs
and actions specific to mAb development needs are ex-
pected to be taken by the State.
Functions of mAb innovation system in China
Based on the results from our analysis, the function per-
formance of the mAb innovation system in China can be
summarized as follows (Figure 1):
 Entrepreneurial activity (F1) is prospering, with a
value chain clearly dominated by foreign players
since the last century. However, China’s mAb supply
chain is growing rapidly and expected to become
one of the top 10 largest in the near future.
 Knowledge development (F2) is being driven by
incentives such as the R&D subsidies from the State
and corporate R&D efforts, and innovation pressure
such as fierce price competition from the leading
countries and the need to improve antibody
expression performance.
 Knowledge diffusion (F3) has been best served over
the last 10 years through information exchange in
networks and technology transfer between
developed countries and China. Clearly, the mAbs
leading enterprises like CPGJ were driving this
growth and the national policies were channelling
much of this demand towards domestic suppliers.
 Guidance of search (F4) has improved. The early
transfer successes helped to highlight the need for
independent innovation and competitive designs. As
operators of mAbs, the enterprises had experienced
a downside and had access to first-information of
the strengths and weaknesses of their technologies.
 Market formation (F5) is not strong enough and
there are many replacement drugs to share the
market. However, high potential niche markets
(export and globalization) have been explored.
 Resource mobilisation (F6) or resource supply
situation has improved in that some resource
categories are supported by the State (financial and
industrial resources); however, for others there are
still obstacles on the path to professional
industrialization (human and infrastructural
resources).
 Advocacy coalition or legitimacy (F7) has gained
momentum due to the government policies of The
Eleventh Five-year Plan in 2007 and the national
projects named as the “973 Program” and the “863
Program”. The successes in building a domestic
mAbs industry and the increase of the targets have
reinforced the legitimacy of the technology
furthermore.
In general, the virtuous circle in China starts with F4:
‘Guidance of the search’. The state fully realized the unique
opportunities of mAb as an emerging technology and set
the direction of mAb industry development in China. Moti-
vated by the state encouragement, entrepreneurial activities
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(F1) were undertaken by different types of entrepreneurs.
Then, targeted mAb technologies were developed (F2) and
diffused (F3) through networking among firms and univer-
sities. In particular, in order to make further technology
development possible and knowledge diffusion, the govern-
ment established a state-level scientific research system and
contributed to international cooperation. The rapid tech-
nology development and diffusion provided further advo-
cacy coalition (F7) for mAb in China. In this case, the
legitimacy supported by the State is beginning to stimulate
market formation (F5) and mobilize several types of
resources (F6), including finance, human resources, etc.,
into the mAb industry. Thus, a complete virtuous cycle of
the mAb innovation system has been established and is op-
erating in China.
To sum up the experience, the main force behind the
development of mAb in China has been the strong polit-
ical commitment to mAb technology, which activated
other functions of the mAb innovation system. Positive
feedback loops have been established with the legitimacy
of this technology elevated with knowledge development
and market formation. The regulatory mechanisms have
Table 3 Biopharmaceutical regulations and influences related to mAbs
Year Title Institute Content Aims Influence/mAb






given priority to develop the
vaccine
To lay a foundation for further
technology development
Focus on vaccine, mAb
industry in China has not
developed well








Reaffirm a fact that biotechnology
is an emerging technology and
the focus of the future high
technology industry tool of
catching up is very important
To make enterprises to be
innovators, cultivate a group of
world-class scientists and
endeavour to turn out a batch
of influential breakthroughs
Middle and small enterprises










The overall planning and
deployment of biological industry.
Four out of nine companies
involved in biomedical field
















Biotech drugs should be
developed for the treatment of
common and serious diseases
To accelerate realization of the
aim of fostering
biopharmaceutical industry into
a strategic pillar in industry
Promote the cooperation and
restructure between business-
to-business, enterprises and









From the aspects of the fiscal and
taxation financial policies to
speed up the cultivation and
development of strategic
emerging industries




Clearly fefine the position of




SFDA Drugs in the list of essential
medicines are to meet the needs
of basic medical and health care
The dosage form is appropriate,
the price is reasonable, and can
guarantee the supply, the public
can have equitable access to
medicine
To protect people’s health, to
meet people's needs, and to
make the country resources get
the most reasonable use
mAbs gradually listed on the
catalogue, expanded the
market
2012 “Twelfth – five” Plan The State
Council
Discovery of new target,
construction of humanized
antibodies, development of




To carry out the innovation-
driven development strategy,




rapidly; enterprises are guided
to speed up R&D of
“Me-better” drugs





Emphasize R&D of new drugs for
major diseases, speed up the
process of therapeutic antibody
innovation, give support to
develop antibody production
industrialization
To get significant results in the
field of antibody and reach
world-class levels in a decade
Get special funds to support
R&D, mAbs for anti-tumour
advanced rapidly
Note: “SFDA” is the former name of the China Food and Drug Administration.
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successfully contributed to the emergence of a massive
mAb innovation system in China.
Discussion
To distinguish the characteristics of the mAb innovation
system in China, a series of comparative discussions are
presented herein. First, we compare the Chinese mAb
innovation system with that of the United States, which
is regarded as the leading mAb innovation system in the
world. Second, we compare it with the mAb innovation
system in India, which is rapidly catching up in the glo-
bal frontier. Third, a comparison between mAb and
pharmaceuticals in China is conducted. With these com-
parative analyses, a deeper understanding about how the
mAb innovation system in China was founded will be
obtained. After these comparative discussions, implica-
tions from this study will be presented to provide refer-
ences for how to build innovation system to seize
emerging technologies.
Comparison of mAb development between the United
States and China
For mAb industry development, the United States has
significant advantages of conducting research and manu-
facturing products [44]. The mAb production capacity
of the United States is ranked as the first in the world,
drawing on the production bases rooted from its trad-
itional pharmaceutical industry. There is large produc-
tion capacity gap between China and the United States.
In the technological aspect, mAb products in the United
States belong to the “first-class technology” product class
and are fully human. The United States has gathered the
world’s top academic and research institutions. Viewed
from the technology resource perspective, the United
States has conducted its independent R&D. Patents can
be transferred freely between different actors and
converted with flexibility into commercialization [45],
which is what China still lags behind.
Furthermore, actors in the United States and their ac-
tivities are playing crucial roles in the progress of mAb
industrialization; in some ways, even more than the
State itself. With respect to the financial system, for in-
stance, firstly, the combination of big pharma and ven-
ture capital is a basic pattern for the biotechnological
entrepreneurship model in the United States. Secondly,
there are several entrepreneur companies in the United
States, who are growing fast as the leading power in
mAbs. Thirdly, the mAb companies from the United
States have enough capabilities to compete in the global
market and to hold their leading market position. Fi-
nally, the federal government’s policy, plus special plans
or projects of the various states, make policies flexible
for mAb development and commercialization [46].
In summary, functions of the mAb innovation system
in the United States work favourably to its knowledge
development (F2) and research advancement guided by
the ever-increasing high expectations (F4). The entrepre-
neurial activity (F1) is outstanding in leading to more
knowledge formation (F2) and lobbying (F7) for better
conditions. Clearly, the United States and China are
moving in the same direction for technology develop-
ment, but not enjoying the same status as competitors.
Comparison of mAb development between India and
China
In terms of corporate behaviour, the mAb actors in India
cooperate more actively with other countries. For ex-
ample, they have deep cooperation with the United
States and Cuba to absorb mature mAb technologies. In
terms of market positioning, India started by developing
the overseas market and hit back to the domestic market
with lower prices [47]. In terms of the financial policy,
the government is not inclined to support enterprises
since most of the national funding is allocated to the sci-
entific research institutions. The main financial re-
sources for enterprises come from venture capital.
Scientific research institutions are still the main innov-
ator of Indian mAb industry [46]. As for the technical
route, China and India’s clinical trials both started using
mouse antibodies, then transiting to human. With
regards to the development strategy, they both went
from imitation to innovation [48]. Concerning the indus-
trial composition, both mAb industries are constituted
mainly by middle- and small-sized enterprises and both
countries are at the start-up stage. As for the develop-
ment bottleneck, China and India are both restricted by
technology and production capacity [45, 49].
However, the question remains as to why India’s devel-
opment in the mAb industry is faster than that of China
[50]. The key lies in the loose policy of generic drug and
Figure 1 Overview of reinforcing cycles within an innovation
system of mAb in China. F1, Entrepreneurial activities; F2, Knowledge
development; F3, Knowledge diffusion through networks; F4,
Guidance of the search; F5, Market formation; F6, Resource
mobilisation; F7, Advocacy coalition.
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tight cooperation in the domestic and overseas endeav-
ours. It also imitated the production–marketing model
of pharmaceuticals. Since the revision of India’s patent
law in 2005, India’ mAbs have occupied a larger market
share around the world, laying the foundation for its
internationalization [51]. India took advantage of the
innovation ability of its leading companies to unite into
one company [52], and built a Bio-Valley around Bom-
bay bringing obvious advantages in market reaction [53].
In summary, the virtuous cycle of mAb innovation sys-
tem in India starts with ‘entrepreneurial activities’ (F1).
The actors tried to lobby the government to create legit-
imacy (F7) and make resource mobilisation (F6) but the
practical results are disappointing. Then, they turned to
improved behaviour (F1) to build up new overseas mar-
kets (F5). India and China are on the same technical
route, but with different technologies and market strat-
egies [54].
Comparison between mAbs and pharmaceuticals in China
Pharmaceuticals in China have been developed and mar-
keted since the 1950s. With regards to enterprise behav-
iour, the production of pharmaceuticals accounts for a
large market share and represents a large industrial clus-
ter. Further, there are various forms of cooperation on
academic exchange and financial investments between
these enterprises. With regards to market performance,
while mAbs have to be promoted exclusively through
academic channels, the pharmaceuticals industry in
China has an existing mature market network and can
be promoted through a variety of channels. The
experience of the Chinese mAb industry compared with
that of pharmaceuticals is summarized in Table 4.
At the technological level, domestic mAb products are
diversified and developed as biosimilar to the foreign
countries’ core technology, albeit with different targets.
In contrast, pharmaceuticals can be manufactured com-
pletely as generics. As a consequence of lack of
innovation investment in the domestic pharmaceuticals
industry, a large number of redundant constructions ap-
peared. Compared with other enterprises, the number of
mAb enterprises is very small, and are all small- and
medium-sized businesses. Their product lines and pro-
motion strategies are undiversified, with less interaction
with each other. Among pharmaceutical enterprises,
there are some big and prestigious companies with prod-
uct diversification and diversified sales channels [55].
The cooperation or merger between such enterprises oc-
curs frequently. As a result, these two types of products
have different performance profiles in the market. Ac-
cording to different technology levels, mAb have high
technical barriers to entry and need high regulatory
standards. On the other hand, for pharmaceuticals, their
low regulatory standards and low entry barriers are likely
to lead to the disorder of market competition. In
addition, the funding mechanisms for pharmaceuticals
and biopharmaceutical drugs such as mAbs are different in
China [56]. In general, compared with pharmaceuticals,
functions of mAbs start with entrepreneurial activities.
Therefore, improving products and manufacturer capability
(F2) is the approach to lobbying for better economic condi-
tions in order to make further technology development
Table 4 Comparison between mAbs and pharmaceuticals in China
mAbs Pharmaceuticals
Specificity High Very low
Side effect Big (early products) Very big





Objective Prevention and control of
major diseases
People’s basic life safety
Technology source Transfer of key technology All generic
Cross-disciplines Biology: proteomics, genetic
engineering
Combining with biology, traditional
Chinese medicine
Level Starting period Mature period
Industry threshold High investment threshold,
high barriers of entry
Low investment threshold, low
barriers of entry
Actor scale Individual leading enterprise Most of enterprises in China
Actor Academies Enterprises
Market strategy Academic promotion Hospital, pharmacy
Bottleneck Large scale production Hard to R&D, price controls strict, over capacity
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possible (F7) and maintain fairer competition in the domes-
tic market.
Implications
This study on the mAb innovation system in China
yields various management and policy implications.
Compared with the development of mAbs in other
countries, such as United States and India, their devel-
opment in China is different. The virtuous circle of mAb
innovation system in China starts with government’s
strong guidance for industrial direction, and then moves
to entrepreneurship and technology development and
diffusion, both of which are strongly supported by the
government. Such an innovation system experience has
at least two important implications.
First, the experiences of mAb development in China
imply that an innovation system could not be founded
by a single actor. On the contrary, to establish an
innovation system to seize the emerging technology,
multiple types of actors need to be gathered and work
collectively to ensure that an innovation system can be
founded and managed in an efficient way. In the process,
the government as a powerful actor, is always required
to play the leading role at the earliest stage. However, to
stimulate the internal dynamics of an innovation system,
the government needs to transfer the leading role to
entrepreneurial firms and research institutes in the next
stages. This role-transferring process is very important
for the maturity of an innovation system.
Second, the connection between innovation systems
and research systems is crucial for the sustainable devel-
opment of emerging technologies such as mAbs. As
shown in this study, having realized the challenges and
uncertainties of mAbs as a new emerging biopharma-
ceutical technology, China has made great investment in
establishing a research system in its universities and re-
search institutes. While technology transfer from other
countries such as Cuba and the United States could pro-
vide opportunities to catch up with the international
mAb frontiers in the short term, China is clearly con-
scious of the impact of its research system on its
innovation system. With political guidance on encour-
aging and supporting linkages between firms and aca-
demic organizations, the connection between the
research system and the innovation system has never
been so accentuated.
Conclusion
This study finds that an innovation system for mAb has
been initially established in China to seize this emerging
biotechnology opportunity. Such an innovation system
was stimulated by the strong policy commitment from
the government at the beginning but was later strength-
ened by entrepreneurial activities. MAb innovators in
China are capitalizing on opportunities to participate in
the development of an innovative drug value chain while
strengthening their capabilities to interconnect and com-
pete with established companies of developed countries.
In the long run, the build-up of the research system for
mAbs in China is expected to lead to more driving
forces in the mAb innovation system.
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